$ATRA

Atara Biotherapeutics, Inc.

Atara Biotherapeutics develops T-cell immunotherapies for cancer and autoimmune diseases using an allogeneic, off-the-shelf platform. Its main product is tab-cel, an EBV-specific T-cell therapy marketed as Ebvallo in the European Economic Area, the United Kingdom and Switzerland, and in Phase 3 development in the U.S. for EBV-positive post-transplant lymphoproliferative disease. Pierre Fabre holds worldwide rights to research, develop, manufacture, commercialize and distribute tab-cel. Atara is eligible for milestone payments and royalties on sales under its agreement with Pierre Fabre. Atara paused its allogeneic CAR T programs, including ATA3219 and ATA3431, in March 2025 and discontinued development of ATA188. It retains patent and related rights for ATA3219 and ATA3431 while evaluating options for those programs. Atara is headquartered in Thousand Oaks, California.

No enriched coverage for $ATRA in the last 7 days.

No SEC Form 4 filings for $ATRA in the last 30 days.

See all $ATRA insider activity →
Med

Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027 Approval of BLA would unlock a $31 Million milestone payment from Pierre Fabre Laboratories Nine-

ATRA sentiment & insider activity

Recent ATRA coverage spans earnings, financial news and regulation.

What's driving ATRA

AlphAI scores every news story that mentions ATRA with an AI model for sentiment and relevance, and aggregates insider trades from Atara Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ATRA

Score
$ATRAMedEarnings

Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027 Approval of BLA would unlock a $31 Million milestone payment from Pierre Fabre Laboratories Nine-

$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Top insider buys and sells disclosed for Friday

Enovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.

Related tickers